This technology involves pharmaceutical compositions, food compositions, and food additives for the prevention and treatment of bone diseases, using the Propionibacterium freudenreichii MJ2 strain (accession number KCCM12272P), its culture medium, or heat-killed cells as active ingredients. It targets a wide range of bone conditions, including osteoporosis, bone defects, various fractures, osteomalacia, osteogenesis imperfecta, and degenerative bone diseases.
Existing osteoporosis treatments such as estrogen, selective estrogen receptor modulators, bisphosphonates, calcitonin, and parathyroid hormones have been associated with safety concerns like stroke, coronary artery disease, and venous thrombosis, and can even cause bone loss at high doses. While some reports suggest certain probiotics increase bone density in animals, there has been a lack of microbial materials that are safe for long-term consumption while directly promoting bone formation.
This technology utilizes the MJ2 strain, as well as heat-killed cells obtained by culturing the strain under anaerobic conditions, as active ingredients to promote osteoblast differentiation and increase calcium accumulation in bone cells. Because it can be used in the form of live bacteria, culture medium, or heat-killed cells, it offers flexibility in formulation and storage. It can be applied to bone health supplements for postmenopausal women, adjuvant therapies for geriatric osteoporosis, and functional additives for dairy or fermented foods, providing a safe, microbial-based bone-forming material that complements existing osteoporosis drugs that are difficult to take long-term.
N/A
